STARPHARMA HOLD/S (OTCMKTS:SPHRY) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report released on Wednesday, ValuEngine reports.

SPHRY stock traded down $0.24 during midday trading on Wednesday, hitting $7.68. 325 shares of the company’s stock were exchanged, compared to its average volume of 1,998. STARPHARMA HOLD/S has a 12-month low of $6.61 and a 12-month high of $11.87. The firm has a 50 day moving average price of $8.30 and a 200-day moving average price of $8.54.


Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom.

Featured Article: What Factors Can Affect Return on Equity?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for STARPHARMA HOLD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STARPHARMA HOLD/S and related companies with's FREE daily email newsletter.